Drug intelligence / Profile preview

anti-COVID-19 human immunoglobulin

Development stage: Unknown
Lead developer: Lifefactors Zona Franca
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-COVID-19 human immunoglobulin (Lifefactors) is a biologic passive immunotherapy developed by the Colombian pharmaceutical company Lifefactors Zona Franca, SAS. It is an intravenous immunoglobulin (IVIG) product derived from human plasma containing high titers of neutralizing antibodies (IgG) against SARS-CoV-2. The product is designed to provide immediate immune protection to hospitalized patients with early-stage COVID-19 by neutralizing the virus and potentially modulating the inflammatory response. It has been evaluated in a Phase 2/3 clinical trial in Colombia, comparing its efficacy and safety to convalescent plasma and standard of care in hospitalized patients.

Other names: IV Anti COVID-19 IgGanti-COVID-19 human immunoglobulin-Lifefactors Zona Franca, SAS-COVID-19Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.SAnti-COVID19 human immunoglobulin produced by Lifefactors Zona Franca S.A.SAnti-COVID 19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on anti-COVID-19 human immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-COVID-19 human immunoglobulin.

Explore the full profile